Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers

Levva, Sofia; Kotoula, Vassiliki; Kostopoulos, Ioannis; Manousou, Kyriaki; Papadimitriou, Christos; Papadopoulou, Kyriaki; Lakis, Sotiris; Koukoulias, Kiriakos; Karavasilis, Vasilios; Pentheroudakis, George; Balassi, Eufemia; Zagouri, Flora; Kaklamanos, Ioannis; Pectasides, Dimitrios; Razis, Evangelia; Aravantinos, G.; Papakostas, Pavlos; Bafaloukos, Dimitrios; Rallis, Grigorios; Gogas, Helen; Fountzilas, George

doi:10.21873/cgp.20030

Cited by 34 publications

(32 citation statements)

References 87 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study is the first to report that TNBCs have a much higher risk of secondary lung cancers. Epidermal growth factor receptor (EGFR) expression is reported in greater than 50% of TNBCs and correlates negatively with survival in these patients ( 15 – 17 ). Overexpression of EGFR in lung adenocarcinomas and TNBCs may provide one clue for common etiologic pathways ( 18 , 19 ).…”

Section: Discussionmentioning

confidence: 99%

Second Primary Lung Cancer After Breast Cancer: A Population-Based Study of 6,269 Women

et al. 2018

View full text Add to dashboard Cite

Purpose: Breast cancer (BC) and lung cancer are the most two common cancers with highest morbidity and mortality for women. With prolonged survival, there comes the possibility that BC patients will develop second primary cancers. We evaluate the characteristics, incidence and survival of second primary non-small cell lung cancer (BC-NSCLC) and small cell lung cancer (BC-SCLC) after breast cancer.Patients and methods: Second primary lung cancer risks using standardized incidence ratios (SIRs) [95% confidence intervals (95% CIs)] were calculated among breast cancer patients in SEER-18 (2000–2014). Survival outcomes were also analyzed for both BC-NSCLC and BC-SCLC.Results: A total of 6,269 second lung cancer patients after a localized or regional BC were identified. The incidence rate was modestly higher compared to the general population (SIR = 1.03; 95%CI: 1.00–1.06). For ER-, PR- and HER2- groups, SIRs were 1.26, 1.16, 1.13, respectively (all p < 0.05). Triple negative breast cancer (TNBC) patients have an even higher incidence rate of lung cancer (SIR = 1.59, 95%CI: 1.29–1.94). Elevated SIRs were also observed among the following groups: within 1 year after BC diagnosed, a young age at BC diagnosed, black people, poorly or undifferentiated histological grade of breast cancer. Median survival (MST) after localized, regional and distant BC-NSCLC was 68.0, 26.0, and 6.0m. Five-year survival rates for BC-NSCLC were 53.9, 29.8 and 5.7% in each stage, which were significantly higher compared to first primary NSCLC (all p < 0.001). ER-/PR- or TNBC were unfavorable prognostic factors for BC-NSCLC. The survival rates of BC-SCLC were no significant different compared to first primary SCLC.Conclusion: BC patients, especially for TNBC, are at a high risk of developing second primary lung cancers. BC history may be a favorable prognostic factor for NSCLC (but not SCLC) patients. Clinicians should closely follow up BC patients with high-risk factors.

show abstract

Section: Discussionmentioning

confidence: 99%

Second Primary Lung Cancer After Breast Cancer: A Population-Based Study of 6,269 Women

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Molecular testing was performed in laboratories internationally certified for EGFR mutation testing; 70% of the tumors were analyzed in the AUTH Department of Pathology or Hellenic Foundation for Cancer Research/Hellenic Cooperative Oncology Group Laboratory of Molecular Oncology, and 30% were analyzed in private laboratories, as previously described. 13 Details are provided in the Data Supplement.…”

Section: Methodsmentioning

confidence: 99%

Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities

Fountzilas¹,

Levva²,

Mountzios³

et al. 2018

JGO

Self Cite

View full text Add to dashboard Cite

PurposeBecause of the profound financial crisis that commenced in Greece in 2010, severe cuts in health care spending and other restriction measures led to significant delays in the reimbursement of novel antineoplastic agents. In 2011, the Hellenic Society of Medical Oncology initiated a program of early access to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors for the treatment of patients with advanced, EGFR-mutant non–small-cell lung cancer (NSCLC). We evaluated treatment patterns and clinical outcomes in patients with EGFR-mutant or wild-type disease treated at a large center in Greece throughout the period of financial crisis.Patients and MethodsFrom 2011 through 2015, 252 patients with newly diagnosed advanced NSCLC were treated at the Department of Medical Oncology of the Papageorgiou Hospital, a tertiary cancer center in northern Greece. We retrospectively reviewed patient medical records to obtain clinicopathologic characteristics, EGFR mutation status, and follow-up data. The primary end point was time to treatment failure.ResultsOf the 198 evaluable patients, 25 (12%) had EGFR mutations. All patients with EGFR mutations except one received treatment with an EGFR tyrosine kinase inhibitor. Median times to treatment failure for patients with EGFR-mutant and wild-type disease were 15.8 and 7.1 months, respectively (hazard ratio, 0.58; 95% CI, 0.35 to 0.95; P = .031). There was no difference in overall survival between the two groups (P = .293). No deviation from treatment guidelines or discontinuation of treatment regimens occurred because of logistic reasons or drug shortages.ConclusionDespite restrictions in the reimbursement policy and accompanying controls in the use of high-cost medicines, the national program enabled treatment of patients with EGFR-mutant NSCLC according to established guidelines. Therefore, the clinical outcomes of such patients treated in Greece during the economic crisis were in accordance with international standards.

show abstract

“…9 Two separate studies revealed EGFR activation in 2 GRCC cases, with one of the cases harboring a unique EGFR mutation and gene amplification. 17,18 Our study, based on NGS analysis of 5 GRCC cases, revealed no EGFR genomic alterations in this cancer. 9 ERBB3 (HER3) and ERBB4 (HER4) mutations were not detected in GRCC either.…”

Section: Her Receptors Family In Grccmentioning

confidence: 66%

“…Two studies revealed a low proliferation rate of GRCC, 17,19 whereas the study of Toikkanen and Joensuu 6 indicated a nondiploid nature of GRCC with a high S-phase fraction. Another study carried out by Kim et al 18 Similar to other breast cancer subtypes and cancer in general, the TP53 gene appears to be involved in a subset of GRCCs.…”

Section: Molecular Genetic Characteristics Of Grccmentioning

confidence: 99%

Glycogen-rich Clear Cell Carcinoma of the Breast: A Comprehensive Review

Vranić

Skenderi²,

Beslagic

et al. 2020

Applied Immunohistochemistry &Amp; Molecular Morphology

View full text Add to dashboard Cite

Glycogen-rich clear cell carcinoma (GRCC) is a very rare form of primary breast cancer (< 0.1% of all breast cancers). It is characterized by the presence of neoplastic cells with a glycogen-abundant clear cytoplasm (the Periodic Acid Schiffpositive, diastase-sensitive). The expression of steroid receptors (estrogen and progesterone receptors) has been variably reported (35% to 100% of the cases), whereas most studies reported low human epidermal growth factor receptor 2 positivity in GRCC. High androgen receptor positivity without androgen receptor splice variant-7 was reported in one recent study. Although sparse, the preliminary theranostic data on GRCC indicate the potential of targeted treatments in selected cases (antiandrogen, PIK3CA, and immune checkpoint inhibitors). Because of its rarity, the prognosis for GRCC patients remains controversial. Herein, we comprehensively appraise the epidemiological, morphologic, molecular, and clinical characteristics of this rare mammary malignancy.

show abstract

Prognostic Evaluation of Epidermal Growth Factor Receptor (EGFR) Genotype and Phenotype Parameters in Triple-negative Breast Cancers

Abstract: Abstract. Background: Epidermal growth factor receptor (EGFR) aberrations have been implicated in the pathogenesis

Cited by 34 publications

References 87 publications

Second Primary Lung Cancer After Breast Cancer: A Population-Based Study of 6,269 Women

Second Primary Lung Cancer After Breast Cancer: A Population-Based Study of 6,269 Women

Treating EGFR-Mutated Oncogene-Addicted Advanced Non–Small-Cell Lung Cancer in the Era of Economic Crisis in Greece: Challenges and Opportunities

Glycogen-rich Clear Cell Carcinoma of the Breast: A Comprehensive Review

Contact Info

Product

Resources

About